{"url_path":"/sec/abcl/8-k/2026-06-17/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1703057/0001703057-26-000035-index.html","accession_number":"0001703057-26-000035","cik":"0001703057","ticker":"ABCL","issuer_name":"AbCellera Biologics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1703057/0001703057-26-000035-index.html","primary_entity_key":"0001703057","primary_entity_name":"AbCellera Biologics Inc."},"word_count":87,"has_tables":true,"body_markdown":"Item 9.01    Financial Statements and Exhibits\n\n(d)Exhibits\n\nExhibit\nNo.Description\n\n99.1\n[Press Release issued by AbCellera Biologics Inc. on June](pressreleaseabcellera202.htm)[1](pressreleaseabcellera202.htm)[7](pressreleaseabcellera202.htm)[, 2026.](pressreleaseabcellera202.htm)\n\n104Cover Page Interactive Data File (embedded as Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: June 17, 2026ABCELLERA BIOLOGICS INC.\n\n \n\nBy:/s/ Carl L. G. Hansen\n\nCarl L. G. Hansen, Ph.D.\n\nChief Executive Officer and Director\n\n(Principal Executive Officer)"}